Early Efficacy With Fedratinib in MDS/MPN and CNL Warrants I

David A. Sallman, MD, discusses the potential use of fedratinib to manage symptomatic myelodysplastic syndrome/myeloproliferative neoplasms.

Related Keywords

Tampa , Florida , United States , Davida Sallman , , International Working Group , Malignant Hematology , Moffitt Cancer Center ,